Stents pricing: Govt asks hospitals to make refunds prompt

Prices of coronary stents were slashed by up to 85% last week following complaints of overcharging

stents
Press Trust of India New Delhi
Last Updated : Feb 25 2017 | 5:11 PM IST
No action will be taken against hospitals under the scanner for overcharging on stents if they refund the money to patients before receiving a demand notice, drug price regulator NPPA said.

The National Pharmaceutical Pricing Authority (NPPA) said the matter would end there for such hospitals if there were no further complaints.

"If the hospitals under the scanner refund money to patients before NPPA issues 'demand notice', the matter ends till there is no new complaint," the regulator tweeted.
Explaining that a 'show cause notice' (SCN) is issued for seeking an explanation from the hospital or company, it added that a 'Demand Notice' (DN) is issued when a violation is proved.
The regulator also said that "it would ensure complete audit of their angioplasty bills in the near future" but did not share details citing "request of patients who have got refunds and their concerns of follow-up need in the same hospitals".

The NPPA had on Friday said that its helpline has received complaints against Oxygen Hospital in Rohtak, Haryana and Bharat Heart Institute, Dehradun, Uttarakhand for overcharging on stents.

The regulator had earlier issued show cause notices to Max Hospital, Saket, New Delhi and Nidaan Multispeciality Hospital, Sonepat, Haryana.

It had also said it was investigating overpricing complaints against hospitals such as Lilavati Hospital (Mumbai), Max Saket (New Delhi), Metro Hospital (Faridabad), PGI Chandigarh, Ram Murti Hospital (Bareilly), and has alerted the concerned State Drug Controllers.

However, Max Healthcare and Lilavati Hospital have said they are in compliance with NPPA guidelines and have not overcharged patients for stents.

In a major relief to patients, the NPPA last week slashed prices of coronary stents by up to 85 per cent, capping them at Rs 7,260 for bare metal ones and Rs 29,600 for the drug-eluting variety.


*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 25 2017 | 5:08 PM IST

Next Story